These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 26548578)

  • 1. Combination of Hedgehog inhibitors and standard anticancer agents synergistically prevent osteosarcoma growth.
    Saitoh Y; Setoguchi T; Nagata M; Tsuru A; Nakamura S; Nagano S; Ishidou Y; Nagao-Kitamoto H; Yokouchi M; Maeda S; Tanimoto A; Furukawa T; Komiya S
    Int J Oncol; 2016 Jan; 48(1):235-42. PubMed ID: 26548578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arsenic trioxide prevents osteosarcoma growth by inhibition of GLI transcription via DNA damage accumulation.
    Nakamura S; Nagano S; Nagao H; Ishidou Y; Yokouchi M; Abematsu M; Yamamoto T; Komiya S; Setoguchi T
    PLoS One; 2013; 8(7):e69466. PubMed ID: 23861973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic effect of arsenic trioxide, vismodegib and temozolomide on glioblastoma.
    Bureta C; Saitoh Y; Tokumoto H; Sasaki H; Maeda S; Nagano S; Komiya S; Taniguchi N; Setoguchi T
    Oncol Rep; 2019 Jun; 41(6):3404-3412. PubMed ID: 31002372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using targeted magnetic arsenic trioxide nanoparticles for osteosarcoma treatment.
    Li XS; Li WQ; Wang WB
    Cancer Biother Radiopharm; 2007 Dec; 22(6):772-8. PubMed ID: 18158768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia.
    Katagiri S; Tauchi T; Okabe S; Minami Y; Kimura S; Maekawa T; Naoe T; Ohyashiki K
    Clin Cancer Res; 2013 Mar; 19(6):1422-32. PubMed ID: 23319824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells.
    Nakaoka T; Ota A; Ono T; Karnan S; Konishi H; Furuhashi A; Ohmura Y; Yamada Y; Hosokawa Y; Kazaoka Y
    Cell Oncol (Dordr); 2014 Apr; 37(2):119-29. PubMed ID: 24599717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
    Wang W; Adachi M; Zhang R; Zhou J; Zhu D
    Pancreas; 2009 May; 38(4):e114-23. PubMed ID: 19342982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tranilast enhances the effect of anticancer agents in osteosarcoma.
    Nakashima T; Nagano S; Setoguchi T; Sasaki H; Saitoh Y; Maeda S; Komiya S; Taniguchi N
    Oncol Rep; 2019 Jul; 42(1):176-188. PubMed ID: 31059083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells.
    Lee PC; Kakadiya R; Su TL; Lee TC
    Neoplasia; 2010 May; 12(5):376-87. PubMed ID: 20454509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.
    Murayama T; Kawasoe Y; Yamashita Y; Ueno Y; Minami S; Yokouchi M; Komiya S
    Anticancer Res; 2008; 28(4B):2147-54. PubMed ID: 18751388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma.
    Seki K; Yoshikawa H; Shiiki K; Hamada Y; Akamatsu N; Tasaka K
    Cancer Chemother Pharmacol; 2000; 45(3):199-206. PubMed ID: 10663637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The growth-inhibitory and apoptosis-inducing effect of deferoxamine combined with arsenic trioxide on HL-60 xenografts in nude mice.
    Yu R; Wang D; Ren X; Zeng L; Liu Y
    Leuk Res; 2014 Sep; 38(9):1085-90. PubMed ID: 24908354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of apoptosis in osteogenic sarcoma cells by combination of tumor necrosis factor-related apoptosis inducing ligand and chemotherapeutic agents.
    Sun J; Fu ZM; Fang CQ; Li JH
    Chin Med J (Engl); 2007 Mar; 120(5):400-4. PubMed ID: 17376311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma.
    Tsuchiya H; Mori Y; Ueda Y; Okada G; Tomita K
    Anticancer Res; 2000; 20(1A):235-42. PubMed ID: 10769661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells.
    Castro-Gamero AM; Borges KS; da Silva Silveira V; Lira RC; de Paula Gomes Queiroz R; Valera FC; Scrideli CA; Umezawa K; Tone LG
    Anticancer Drugs; 2012 Jul; 23(6):638-50. PubMed ID: 22382389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLI2 is a novel therapeutic target for metastasis of osteosarcoma.
    Nagao-Kitamoto H; Nagata M; Nagano S; Kitamoto S; Ishidou Y; Yamamoto T; Nakamura S; Tsuru A; Abematsu M; Fujimoto Y; Yokouchi M; Kitajima S; Yoshioka T; Maeda S; Yonezawa S; Komiya S; Setoguchi T
    Int J Cancer; 2015 Mar; 136(6):1276-84. PubMed ID: 25082385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stathmin is key in reversion of doxorubicin resistance by arsenic trioxide in osteosarcoma cells.
    Feng T; Qiao G; Feng L; Qi W; Huang Y; Yao Y; Shen Z
    Mol Med Rep; 2014 Dec; 10(6):2985-92. PubMed ID: 25310700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
    Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
    Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model.
    Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Chawla SP; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Anticancer Res; 2019 Aug; 39(8):4079-4084. PubMed ID: 31366491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ViscumTT induces apoptosis and alters IAP expression in osteosarcoma in vitro and has synergistic action when combined with different chemotherapeutic drugs.
    Kleinsimon S; Kauczor G; Jaeger S; Eggert A; Seifert G; Delebinski C
    BMC Complement Altern Med; 2017 Jan; 17(1):26. PubMed ID: 28061770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.